VAXART INC (VXRT) Stock News

USA - NASDAQ:VXRT - US92243A2006 - Common Stock

0.32 USD

-0.11 (-25.06%)

Last: 7/7/2025, 10:34:23 PM

0.3251 USD

+0.01 (+1.59%)

After Hours: 7/7/2025, 10:34:23 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VXRT Latest News, Press Relases and Analysis

All

Press Releases

13 hours ago - By: Chartmill

News Image

Vaxart Inc (NASDAQ:VXRT) Surges on Stellar Q3 2025 Earnings and $700M Dynavax Deal

17 hours ago - By: Vaxart, Inc.

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

2 days ago - By: Benzinga

A Look at Vaxart's Upcoming Earnings Report

4 days ago - By: Zacks Investment Research - Mentions: FDMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

7 days ago - By: Vaxart, Inc.

Vaxart to Host Upcoming Conference Calls

8 days ago - By: Zacks Investment Research - Mentions: CRNX

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates

9 days ago - By: Dynavax Technologies - Mentions: DVAX

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

9 days ago - By: Dynavax Technologies - Mentions: DVAX

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

a month ago - By: Vaxart, Inc.

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

2 months ago - By: Vaxart, Inc.

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

2 months ago - By: Daniel Houle, Concerned Stockholder of Vaxart, Inc.

Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

2 months ago - By: Vaxart, Inc.

Vaxart Appoints W. Mark Watson as Lead Independent Director

2 months ago - By: Vaxart, Inc.

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

2 months ago - By: Daniel Houle, Concerned Stockholder of Vaxart, Inc.

Concerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special Meeting

2 months ago - By: Vaxart, Inc.

Vaxart Announces Adjournment of Special Meeting of Stockholders

2 months ago - By: Vaxart, Inc.

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

2 months ago - By: Daniel Houle, Concerned Stockholder of Vaxart, Inc.

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

3 months ago - By: Vaxart, Inc.

Vaxart Granted Extension by Nasdaq to Regain Compliance

3 months ago - By: Daniel Houle, Concerned Stockholder of Vaxart, Inc.

Concerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder Rights

3 months ago - By: Zacks Investment Research - Mentions: CASI

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: The Motley Fool

Vaxart Revenue Jumps 520% in Fiscal Q2

3 months ago - By: Benzinga

Vaxart's Earnings: A Preview

3 months ago - By: Zacks Investment Research - Mentions: KPTI

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Vaxart, Inc.

Vaxart CEO Issues Letter to Stockholders

3 months ago - By: Zacks Investment Research - Mentions: SKIN

The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: SEM

Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates

4 months ago - By: Vaxart, Inc.

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

4 months ago - By: OTC Markets - Mentions: OTCM

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

5 months ago - By: Vaxart, Inc.

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders